October 15, 2019 — Royal Philips introduced two new balloons to its Stellarex 0.035-inch low-dose drug-coated balloon ...
Drug-Eluting Balloons
This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.
October 15, 2019
October 10, 2019 — An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no ...
October 10, 2019
Chandan Devireddy, M.D., offers insights about what he saw as the top take aways from the 2019 Transcatheter ...
October 04, 2019
September 20, 2019 — Orchestra BioMed Inc., in partnership with Terumo Corp. announced the company has secured ...
September 20, 2019
August 27, 2019 — Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug ...
August 27, 2019
August 14, 2019 — Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and ...
August 14, 2019
August 2, 2019 — B. Braun Interventional Systems Inc. (BIS) announced the U.S. Food and Drug Administration (FDA) has ...
August 02, 2019
June 13, 2019 — Orchestra BioMed Inc. announced it has formed a global strategic partnership with Terumo Corp. for ...
June 13, 2019
May 29, 2019 — Philips announced the three-year results from the ILLUMENATE Pivotal trial and the ILLUMENATE European ...
May 29, 2019
Concept Medical Inc. Granted Breakthrough Device Designation for MagicTouch Sirolimus Coated Balloon
May 2, 2019 — Concept Medical Inc. (CMI) has been granted Breakthrough Device Designation from the U.S. Food and Drug ...
May 02, 2019
April 24, 2019 — Orchestra BioMed Inc. has secured Breakthrough Device designation by the U.S. Food and Drug ...
April 24, 2019
March 6, 2019 – Swiss-based M.A. MedAlliance SA has been granted Breakthrough Device Designation from the U.S. Food and ...
March 06, 2019
January 28, 2019 — Philips announced the latest pooled analysis of patient-level data of over 2,300 patients treated ...
January 28, 2019
January 17, 2019 — The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers ...
January 17, 2019
September 25, 2018 — Orchestra BioMed Inc. announced the three-year clinical results from its Sirolimus Angioplasty ...
September 25, 2018